On 15 August 2025, Guangzhou Innogen Pharmaceutical Group Co., Ltd. (2591.HK, Innogen) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), being the first IPO after the implementation of revised clawback and pricing mechanism, raising a total of approximately HKD 683 million. CBI is honored to participate in the due diligence work for this IPO Project.

Innogen is principally engaged in the research, development and commercialisation of pharmaceutical products. The Company is primarily engaged in the commercialization of innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist and dedicated to developing therapies for diabetes and other metabolic diseases. 

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, shareholders, suppliers, customers and pre-IPO investors. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting reputation intelligence and related company search. The due diligence project globally covered 8 countries and regions, including China, Hong Kong, Australia, South Korea and the United States, etc.